il13ra2  (R&D Systems)

Journal: Cell reports

Article Title: TGF-β1-mediated intercellular signaling fuels cooperative cellular invasion

doi: 10.1016/j.celrep.2025.115315

Figure Lengend Snippet:

Article Snippet: CD213a2 (IL13Ra2) (APC) , Miltenyi Biotec , Cat#130-128-220; RRID: AB_2928320.

Techniques: Recombinant, Reverse Transcription, Bicinchoninic Acid Protein Assay, Staining, RNA Sequencing

Journal: Acta neuropathologica communications

Article Title: IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

doi: 10.1186/s40478-025-01991-4

Figure Lengend Snippet: Fig. 1 IL13RA2 shows heterogenous expression in human DIPG. (A) IL13RA2 gene expression in pediatric brain tumors from Gump database was ana lyzed using GlioVis (http://gliovis.bioinfo.cnio.es/). Tukey’s Honest Significant Difference (HSD) was performed to compare IL13RA2 gene expression be tween pediatric tumors. Significance was denoted in the graph by one asterisk (*) where p < 0.05, two (**) where p < 0.01, and three (***) where p < 0.001. (B) IL13RA2 histopathological scores of post-mortem patient samples. (C) Representative images of each IL13RA2 histopathological score in post-mortem human pDMG patient samples (top panel) and corresponding H&E stains (bottom panel). Each image includes high-power insets at low-power fields (top right hovering image)

Article Snippet: Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R&D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4 °C.

Techniques: Expressing, Gene Expression

Journal: Acta neuropathologica communications

Article Title: IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

doi: 10.1186/s40478-025-01991-4

Figure Lengend Snippet: Fig. 2 Analysis of GEM models of midline glioma expressing IL13RA2. (A) Visual schematic of RCAS vector generated with PDGFB and IL13RA2 transgenes flanked by recombination att sites used to transfect DF-1 cells. Validation of PDGFB and IL13RA2 expression in DF-1 by (B) flow cytometry and (C) western blot. (D) Comparison of survival for Nestin-Tva; p53fl/fl mice injected at midline location with DF-1 producing virus containing RCAS-CRE and PDGFB or PDGFB + IL13RA2

Article Snippet: Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R&D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4 °C.

Techniques: Expressing, Plasmid Preparation, Generated, Biomarker Discovery, Flow Cytometry, Western Blot, Comparison, Injection, Virus

Journal: Acta neuropathologica communications

Article Title: IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

doi: 10.1186/s40478-025-01991-4

Figure Lengend Snippet: Fig. 4 De novo PDGF-B/ IL13RA2 overexpressing tumors respond to CAR T-cell therapy. (A) Survival analysis of mice with de novo cortical tumor of Nestin- Tva; p53fl/fl/ PTEN fl/fl mice treated with saline (n = 8), non-transduced (NT) T-cells (n = 13) or CAR T-cells (n = 12), ***p < 0.0001. (B) H&E stain of mouse brain from control (left panel) and CAR T-cell-treated (right panel) long-term surviving mice. (C-H) Flow cytometric analysis of tumor microenvironment of nestin-Tva; p53fl/fl/ PTEN fl/fl mice treated with saline (white), non-transduced (NT) T-cells (blue) or CAR T-cells (red)

Article Snippet: Membranes were incubated with anti-IL13RA2 monoclonal antibody (1:1000) (R&D Systems, AF146), anti-HA tag antibody to detect PDGFB (1:1000) (Cell Signaling Technology, 3724), and antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal Antibody (1:1000) (Cell Signaling Technology, 2118) in 5% NFDM-TBST overnight at 4 °C.

Techniques: Saline, Staining, Control